awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
Graphs
1
Q36709312-90519B39-1273-4777-941F-E548C352090A
Q36709312-90519B39-1273-4777-941F-E548C352090A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36709312-90519B39-1273-4777-941F-E548C352090A
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.
P2860
Q36709312-90519B39-1273-4777-941F-E548C352090A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36709312-90519B39-1273-4777-941F-E548C352090A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
acb470dee52f79d07da277cf01b6dfefd4776f1b
P2860
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days